chr6-160706469-A-G
Variant names:
Variant summary
Our verdict is Likely pathogenic. Variant got 6 ACMG points: 8P and 2B. PP5_Very_StrongBP4BS1_Supporting
The NM_000301.5(PLG):c.112A>G(p.Lys38Glu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00498 in 1,613,830 control chromosomes in the GnomAD database, including 36 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: 𝑓 0.0028 ( 2 hom., cov: 32)
Exomes 𝑓: 0.0052 ( 34 hom. )
Consequence
PLG
NM_000301.5 missense
NM_000301.5 missense
Scores
9
10
Clinical Significance
Conservation
PhyloP100: 1.66
Genes affected
PLG (HGNC:9071): (plasminogen) The plasminogen protein encoded by this gene is a serine protease that circulates in blood plasma as an inactive zymogen and is converted to the active protease, plasmin, by several plasminogen activators such as tissue plasminogen activator (tPA), urokinase plasminogen activator (uPA), kallikrein, and factor XII (Hageman factor). The conversion of plasminogen to plasmin involves the cleavage of the peptide bond between Arg-561 and Val-562. Plasmin cleavage also releases the angiostatin protein which inhibits angiogenesis. Plasmin degrades many blood plasma proteins, including fibrin-containing blood clots. As a serine protease, plasmin cleaves many products in addition to fibrin such as fibronectin, thrombospondin, laminin, and von Willebrand factor. Plasmin is inactivated by proteins such as alpha-2-macroglobulin and alpha-2-antiplasmin in addition to inhibitors of the various plasminogen activators. Plasminogen also interacts with plasminogen receptors which results in the retention of plasmin on cell surfaces and in plasmin-induced cell signaling. The localization of plasminogen on cell surfaces plays a role in the degradation of extracellular matrices, cell migration, inflamation, wound healing, oncogenesis, metastasis, myogenesis, muscle regeneration, neurite outgrowth, and fibrinolysis. This protein may also play a role in acute respiratory distress syndrome (ARDS) which, in part, is caused by enhanced clot formation and the suppression of fibrinolysis. Compared to other mammals, the cluster of plasminogen-like genes to which this gene belongs has been rearranged in catarrhine primates. [provided by RefSeq, May 2020]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_pathogenic. Variant got 6 ACMG points.
PP5
Variant 6-160706469-A-G is Pathogenic according to our data. Variant chr6-160706469-A-G is described in ClinVar as [Likely_pathogenic]. Clinvar id is 13583.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr6-160706469-A-G is described in Lovd as [Pathogenic]. Variant chr6-160706469-A-G is described in Lovd as [Likely_pathogenic].
BP4
Computational evidence support a benign effect (MetaRNN=0.19466236). . Strength limited to SUPPORTING due to the PP5.
BS1
Variant frequency is greater than expected in population nfe. gnomad4 allele frequency = 0.00277 (422/152322) while in subpopulation NFE AF= 0.00475 (323/68012). AF 95% confidence interval is 0.00432. There are 2 homozygotes in gnomad4. There are 178 alleles in male gnomad4 subpopulation. Median coverage is 32. This position pass quality control queck. Existence of Clinvar submissions makes me limit the strength of this signal to Supporting
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes 0.00277 AC: 422AN: 152204Hom.: 2 Cov.: 32
GnomAD3 genomes
AF:
AC:
422
AN:
152204
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00295 AC: 742AN: 251130Hom.: 4 AF XY: 0.00280 AC XY: 380AN XY: 135720
GnomAD3 exomes
AF:
AC:
742
AN:
251130
Hom.:
AF XY:
AC XY:
380
AN XY:
135720
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00521 AC: 7610AN: 1461508Hom.: 34 Cov.: 31 AF XY: 0.00493 AC XY: 3587AN XY: 727074
GnomAD4 exome
AF:
AC:
7610
AN:
1461508
Hom.:
Cov.:
31
AF XY:
AC XY:
3587
AN XY:
727074
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome 0.00277 AC: 422AN: 152322Hom.: 2 Cov.: 32 AF XY: 0.00239 AC XY: 178AN XY: 74490
GnomAD4 genome
AF:
AC:
422
AN:
152322
Hom.:
Cov.:
32
AF XY:
AC XY:
178
AN XY:
74490
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
31
ALSPAC
AF:
AC:
37
ESP6500AA
AF:
AC:
3
ESP6500EA
AF:
AC:
53
ExAC
AF:
AC:
400
Asia WGS
AF:
AC:
3
AN:
3478
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:16Uncertain:2Benign:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:8
| Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Mar 24, 2022 | In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function; Also known as K19E using alternate nomenclature; This variant is associated with the following publications: (PMID: 22995991, 27976734, 28876531, 20981092, 10233898, 30487145, 12850227, 26340456, 12945885, 23629776, 15269832, 16849641, 31980526, 31589614, 12876630, 34426522) - |
| Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 23, 2025 | This sequence change replaces lysine, which is basic and polar, with glutamic acid, which is acidic and polar, at codon 38 of the PLG protein (p.Lys38Glu). This variant is present in population databases (rs73015965, gnomAD 0.5%), and has an allele count higher than expected for a pathogenic variant. This missense change has been observed in individual(s) with plasminogen deficiency and ligneous conjunctivitis (PMID: 10233898, 15269832, 16849641, 23629776, 26340456, 27976734). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 13583). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt PLG protein function with a negative predictive value of 95%. For these reasons, this variant has been classified as Pathogenic. - |
| Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Nov 09, 2023 | - - |
| Likely pathogenic, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | The PLG p.Lys38Glu variant was found in 13 families in Scotland who were identified to have type I plasminogen deficiency (hypoplasminogenaemia) upon donating blood; the variant was reported to be the most common cause of hypoplasminogenaemia in Scotland, with a prevalence of 0.14% (Tefs_2003_PMID:12945885). Three unrelated patients with ligneous conjunctivitis were found to be compound heterozygous for the p.K38E variant; two of these patients presented in infancy while the third patient did not present until age 69. The two patients presenting in infancy both inherited the p.K38E variant from their unaffected fathers. Plasminogen antigen and activity levels were tested in these patients as well as their families; all three compound heterozygous patients with the p.K38E variant had little to no plasminogen antigen or activity, and the two p.K38E heterozygous carriers had decreased activity compared to wildtype (Schuster_1999_PMID:10233898). The variant was identified in dbSNP (ID: rs73015965), ClinVar (classified as pathogenic by Fulgent Genetics, EGL Genetics and Knight Diagnostic Laboratories, Oregon Health and Sciences University and as likely pathogenic by NIHR Bioresource Rare Diseases, University of Cambridge) and LOVD 3.0 (classified as a VUS and pathogenic). The variant was identified in control databases in 817 of 282530 chromosomes (4 homozygous) at a frequency of 0.002892 increasing the likelihood this could be a low frequency benign variant (Genome Aggregation Database March 6, 2019, v2.1.1). The variant was observed in the following populations: European (non-Finnish) in 645 of 128850 chromosomes (freq: 0.005006), Other in 24 of 7220 chromosomes (freq: 0.003324), Latino in 99 of 35438 chromosomes (freq: 0.002794), African in 34 of 24962 chromosomes (freq: 0.001362), European (Finnish) in 13 of 25122 chromosomes (freq: 0.000518) and South Asian in 2 of 30616 chromosomes (freq: 0.000065), but was not observed in the Ashkenazi Jewish or East Asian populations. The p.Lys38 residue is not conserved in mammals and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) provide inconsistent predictions regarding the impact to the protein; this information is not very predictive of pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) do not predict a difference in splicing. One study identified 6 type I plasminogen deficiency patients with homozygous K38E mutations that had a milder clinical course and higher residual plasminogen antigen and activity levels than patients with other plasminogen mutations; a homozygous K38E mutation (and similarly decreased PLG values) was also found in one patient's healthy brother, suggesting incomplete penetrance (Tefs_2006_PMID:16849641). Functional in vitro data determined that secretion of mutant K38E protein from transfected cells was not significantly reduced (Tefs_2006_PMID:16849641). In summary, this variant is considered a hypomorphic allele and in combination with other variants in cis or trans, may result in reduced enzyme activity. Based on the above information this variant meets our laboratory’s criteria to be classified as likely pathogenic. - |
| Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Sep 06, 2018 | - - |
| Likely pathogenic, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital | Mar 04, 2025 | - - |
| Likely pathogenic, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Oct 10, 2024 | PP1_supporting+PM1_supporting+PM3_moderate+PS4_moderate - |
| Likely pathogenic, criteria provided, single submitter | clinical testing | AiLife Diagnostics, AiLife Diagnostics | Mar 30, 2022 | - - |
Plasminogen deficiency, type I Pathogenic:7Uncertain:1
| Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 31, 2018 | - - |
| Pathogenic, no assertion criteria provided | literature only | OMIM | Nov 01, 2006 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Knight Diagnostic Laboratories, Oregon Health and Sciences University | Jan 27, 2016 | The c.112A>G (p.Lys38Glu) missense variant in the PLG gene has been previously reported in numerous affected individuals with autosomal recessive Plasminogen Deficiency and has been shown to segregate with disease in affected family members (Schuster et al., 1999; Schuster et al., 2001). This variant has been observed in affected individuals in trans with multiple variants (Cys122Ter, Arg134Lys, Arg513His, Arg216His, and Leu128Pro) (Schuster et al., 1999; Schuster et al., 2001). Functional studies have shown this variant causes decreased serum plasminogen activity and decreased plasminogen antigen levels (Schuster et al., 1999; Schuster et al., 2001; Tefs et al., 2006). Case-control studies have found this variant to be significantly more prevalent in affected individuals relative to controls (Tefs et al., 2006). This c.112A>G has been reported in the three population databases at a frequency lower than the prevalence of the disease (Exome Sequencing Project [ESP] = 0.616%, 1000 Genomes = 1%, and ExAC = 0.496%). The PLG gene is the only gene in which mutations are known to cause Plasminogen Deficiency. Therefore, this collective evidence supports the classification of the c.112A>G (p.Lys38Glu) as a recessive Pathogenic variant for Plasminogen Deficiency. - |
| Pathogenic, no assertion criteria provided | curation | Reproductive Health Research and Development, BGI Genomics | Jan 06, 2020 | NM_000301.3:c.112A>G in the PLG gene has an allele frequency of 0.005 in European (non-Finnish) subpopulation in the gnomAD database. This variant has been observed in affected individuals in trans with multiple variants (Cys122Ter, Arg134Lys, Arg513His, Arg216His, and Leu128Pro) (PMID: 10233898; 12850227). Functional studies have shown this variant causes decreased serum plasminogen activity and decreased plasminogen antigen levels (PMID: 16849641). Case-control studies have found this variant to be significantly more prevalent in affected individuals relative to controls (PMID: 16849641). Taken together, we interprete this variant as Pathogenic/Likely pathogenic. ACMG/AMP Criteria applied: PM3_VeryStrong; PS3; PS4; PP4. - |
| Uncertain significance, flagged submission | clinical testing | ISTH-SSC Genomics in Thrombosis and Hemostasis, KU Leuven, Center for Molecular and Vascular Biology | - | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Mendelics | May 04, 2022 | - - |
| Likely pathogenic, criteria provided, single submitter | research | NIHR Bioresource Rare Diseases, University of Cambridge | Feb 01, 2019 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Dec 01, 2023 | Variant summary: PLG c.112A>G (p.Lys38Glu) results in a conservative amino acid change located in the PAN/Apple domain (IPR003609) of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.003 in 251130 control chromosomes in the gnomAD database, including 4 homozygotes. The observed variant frequency is approximately 3-fold of the estimated maximal expected allele frequency for a pathogenic variant in PLG causing Plasminogen Deficiency phenotype (0.0011), suggesting that the variant could be benign. However, c.112A>G has been reported in the literature as a biallelic genotype in many individuals affected with Plasminogen Deficiency/Ligneous Conjuctivitis, including cases where it has been found in trans with loss of function variants and it has been found to segregate with disease in multiple unrelated families (e.g. Schuster_1999, Tefs_2006). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function and found that the secretion kinetics of the variant were normal, however, this study did not directly assess PLG activity (Tefs_2006). The following publications have been ascertained in the context of this evaluation (PMID: 10233898, 16849641). Twelve submitters have cited clinical-significance assessments for this variant to ClinVar after 2014 with conflicting assessments. Ten submitters classified the variant as pathogenic/likely pathogenic, one submitter classified it as uncertain significance and one as benign. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Plasminogen deficiency, type I;C5543503:Angioedema, hereditary, 4 Pathogenic:1
| Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Mar 25, 2024 | - - |
Deep venous thrombosis Uncertain:1
| Uncertain significance, flagged submission | clinical testing | ISTH-SSC Genomics in Thrombosis and Hemostasis, KU Leuven, Center for Molecular and Vascular Biology | - | - - |
Otitis media, susceptibility to Benign:1
| Benign, flagged submission | research | Santos-Cortez Lab, University of Colorado School of Medicine | Jul 26, 2019 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Uncertain
CADD
Benign
DANN
Uncertain
DEOGEN2
Uncertain
.;D;D
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Benign
N
LIST_S2
Benign
T;T;T
M_CAP
Uncertain
D
MetaRNN
Benign
T;T;T
MetaSVM
Uncertain
D
MutationAssessor
Uncertain
.;M;.
PrimateAI
Benign
T
PROVEAN
Benign
N;N;N
REVEL
Uncertain
Sift
Uncertain
D;D;D
Sift4G
Uncertain
D;T;D
Polyphen
0.88
.;P;.
Vest4
MVP
MPC
0.70
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at